---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-078145"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:55:30.110028+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics announces positive Phase 1b data for briquilimab in Fanconi Anemia; all 3 patients engrafted

## Summary
- All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery.
- Briquilimab was well tolerated without any complications; no briquilimab-related adverse events or toxicities.
- Study expansion to Phase 2a is ongoing, led by Stanford.
- Data to be presented at 2023 Fanconi Anemia Research Fund Scientific Symposium (Sept 28-Oct 1).

## SEC filing metadata
- accession: 0001213900-23-078145
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023078145/0001213900-23-078145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023078145/ea185533-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-078145
- JSON: https://secwatch.observer/filing/0001213900-23-078145.json
- Plain text: https://secwatch.observer/filing/0001213900-23-078145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.